FindTrial
Sign In

Adjuvant Therapy Optimization Guided by Major Pathological Response: A Multicenter Retrospective Analysis in Non-Small Cell Lung Cancer after Neoadjuvant Treatment

Adjuvant Therapy Optimization Guided by Major Pathological Response: A Multicenter Retrospective Analysis in Non-Small Cell Lung Cancer after Neoadjuvant Treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109490
Enrollment
Unknown
Registered
2025-09-19
Start date
2025-10-01
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

MPR group:None
non-MPR group:None

Sponsors

Fujian Medical University Union Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Pathological diagnosis of non-small cell lung cancer (adenocarcinoma or squamous cell carcinoma); 2. Receiving neoadjuvant chemotherapy (NCT) or chemotherapy combined with immunotherapy (NICT), followed by radical surgical resection; 3. No other anti-tumor therapy before neoadjuvant therapy; 4. Have complete clinical and pathological data

Exclusion criteria

Exclusion criteria: 1. Those who cannot tolerate neoadjuvant therapy or whose tumor is found to be unresectable during surgery 2. History of other malignant tumors in the past or at the same time; 3. Pregnant or lactating women; 4. Those who survive less than 1 month after surgery or have incomplete clinical data.

Design outcomes

Primary

MeasureTime frame
Overall survival;—

Countries

China

Contacts

Public ContactShuchen Chen

Fujian Medical University Union Hospital

cscdoctor@163.com+86 139 5020 7801

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026